New strategy aims to shrink liver tumors for surgery

NCT ID NCT07480382

Not yet recruiting Disease control Sponsor: Hong Wu Source: ClinicalTrials.gov ↗

Summary

This study tests a combination approach for patients with liver cancer that cannot be removed by surgery initially. The treatment uses a two-part strategy: first, a procedure to help the healthy part of the liver grow larger, and second, a combination of localized and drug therapies to shrink the tumor. The main goal is to see if this approach can make the cancer operable so surgeons can safely remove it.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INITIALLY UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 614000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.